Asia-Pacific cell line development market revenue is expected to register a 13% CAGR during 2020 to 2026, driven by the presence of a large patient pool suffering from various chronic and infectious diseases. Growing investments in stem cell research, coupled with surge in demand for regenerative medicine, will also favor the regional industry growth.

According to the report, the immunohistochemistry market was worth US $1.78 billion in 2018 and is expected to expand with a CAGR of 7.3% through the year 2027